Details of the Drug-Related molecule(s) Interaction Atlas

adenosine diphosphate Drug Info

Adenosine diphosphate; 58-64-0; ADP; Adenosine 5'-(trihydrogen diphosphate); adenosine pyrophosphate; adenosine 5'-pyrophosphate; ADP (nucleotide); adenosine-diphosphate; 5'-Adenylphosphoric acid; 5'-Adp; Adenosindiphosphorsaeure; Adenosine 5'-pyrophosphoric acid; Adenosine-5'-diphosphat; Adenosine 5'-diphosphoric acid; Adenosine diphosphoric acid; Ado-5'-P-P; UNII-61D2G4IYVH; H3adp; BRN 0067722; CHEBI:16761; EINECS 200-392-5; 61D2G4IYVH; CHEMBL14830

Cross-matching ID

PubChem CID

6022

ChEBI ID

CHEMBL14830

CAS Number

CAS 58-64-0

TTD Drug ID

DMFUHKP

General Information of Drug (ID: DMFUHKP)

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P2Y purinoceptor 13 (P2RY13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2MeSATP	DMUE0W6	Discovery agent	N.A.	Investigative	[4]
PPADS	DMWHN3T	Discovery agent	N.A.	Investigative	[4]
2MeSADP	DMGADQ1	Discovery agent	N.A.	Investigative	[4]
ATPgammaS	DMXHQIN	Discovery agent	N.A.	Investigative	[4]
2MeSAMP	DMBO2DC	Discovery agent	N.A.	Investigative	[4]
MRS2211	DM2G5ZE	Discovery agent	N.A.	Investigative	[12]
[33P]2MeSADP	DM218VZ	Discovery agent	N.A.	Investigative	[4]
MRS2603	DMNGC79	Discovery agent	N.A.	Investigative	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Drug(s) Targeting P2Y purinoceptor 12 (P2RY12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[3]
Prasugrel	DM7MT6E	Acute coronary syndrome	BA41	Approved	[13]
Brilinta	DMBR01X	Acute coronary syndrome	BA41	Approved	[14]
Cangrelor	DM8JRH0	Thrombosis	DB61-GB90	Approved	[15]
INS-50589	DMKZUVC	Cardiovascular disease	BA00-BE2Z	Phase 2	[16]
Elinogrel	DMA4BRV	Myocardial infarction	BA41-BA43	Phase 1	[17]
ARL-67085	DMY5IM2	Thrombosis	DB61-GB90	Phase 1	[18]
2MeSADP	DMGADQ1	Discovery agent	N.A.	Investigative	[19]
2MeSAMP	DMBO2DC	Discovery agent	N.A.	Investigative	[19]
R-138727	DML49FI	Discovery agent	N.A.	Investigative	[20]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting P2Y purinoceptor 1 (P2RY1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2MeSATP	DMUE0W6	Discovery agent	N.A.	Investigative	[2]
PPADS	DMWHN3T	Discovery agent	N.A.	Investigative	[2]
2MeSADP	DMGADQ1	Discovery agent	N.A.	Investigative	[19]
ATPgammaS	DMXHQIN	Discovery agent	N.A.	Investigative	[21]
2',3'-ddATP	DMOB7P6	Discovery agent	N.A.	Investigative	[21]
[35S]ADPbetaS	DMAYPTO	Discovery agent	N.A.	Investigative	[22]
MRS2298	DMZ6EGA	Discovery agent	N.A.	Investigative	[23]
MRS2500	DMNGTOY	Discovery agent	N.A.	Investigative	[24]
2,2'-pyridylisatogen tosylate	DMOQDBA	Discovery agent	N.A.	Investigative	[25]
PMID23368907C16	DMPHKJI	Discovery agent	N.A.	Investigative	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting P2Y purinoceptor 6 (P2RY6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GC021109	DMQBEYV	Alzheimer disease	8A20	Phase 1	[27]
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[5]
2MeSATP	DMUE0W6	Discovery agent	N.A.	Investigative	[5]
RB 2	DMCEFUW	Discovery agent	N.A.	Investigative	[28]
PSB-0952	DMW19LB	Discovery agent	N.A.	Investigative	[28]
5BrUTP	DMEVRH4	Discovery agent	N.A.	Investigative	[5]
MRS2782	DMZSO4R	Discovery agent	N.A.	Investigative	[29]
MRS2578	DMKMPS6	Discovery agent	N.A.	Investigative	[30]
UDP-beta-S	DMMWHAV	Discovery agent	N.A.	Investigative	[31]
Up3U	DMKQWSB	Discovery agent	N.A.	Investigative	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Long transient receptor potential channel 4 (TRPM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[1]
PIP2	DMOZV7N	Discovery agent	N.A.	Investigative	[32]
decavanadate	DMLT1N3	Discovery agent	N.A.	Investigative	[33]
BTP2	DMNM63G	Discovery agent	N.A.	Investigative	[34]
9-phenanthrol	DMJFBQ1	Discovery agent	N.A.	Investigative	[35]
------------------------------------------------------------------------------------

Drug(s) Affected By 5'-nucleotidase (NT5E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[40]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[41]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[42]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[43]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[44]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[45]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Fibrinogen alpha chain (FGA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[7]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[46]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[41]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[47]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[48]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[49]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[52]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Fibrinogen beta chain (FGB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[7]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[46]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[49]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[57]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Fibrinogen gamma chain (FGG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[58]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[46]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[41]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[59]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[60]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[49]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[61]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[63]
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[64]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[65]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[66]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[67]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[68]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[70]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Platelet basic protein (PPBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[72]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[73]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[74]
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[75]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[76]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[41]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[78]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[79]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[80]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[81]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[82]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[83]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[84]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[85]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[86]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[87]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[88]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[89]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[90]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[81]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[91]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[92]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[93]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[80]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[63]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[83]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[84]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By CD40 ligand (CD40LG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[94]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[95]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[96]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[97]
Asasantin	DMCZIHT	Cerebrovascular ischaemia	8B1Z	Approved	[98]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[99]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[100]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[101]
Eptifibatide	DMQXTJS	Acute cardiac ischemic events	BA40.Z	Approved	[102]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[99]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Tyrosine-protein kinase receptor UFO (AXL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[103]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[104]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[105]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[104]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[106]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[107]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[108]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[108]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[108]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Prothrombin (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[109]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[111]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[112]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[113]
Phytonadione	DM8HDOL	Bleeding disorder	GA20-GA21	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[46]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[115]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[116]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Growth arrest-specific protein 6 (GAS6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[41]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[118]
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[119]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[120]
Phosphate	DMUXQG7	Constipation	DD91.1	Approved	[117]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[121]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[122]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[123]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[117]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Long transient receptor potential channel 4 (TRPM4)	TTJ2HKA	TRPM4_HUMAN	Inhibitor (gating inhibitor)	[1]
P2Y purinoceptor 1 (P2RY1)	TTA93TL	P2RY1_HUMAN	Agonist	[2]
P2Y purinoceptor 12 (P2RY12)	TTZ1DT0	P2Y12_HUMAN	Agonist	[3]
P2Y purinoceptor 13 (P2RY13)	TT1FE3L	P2Y13_HUMAN	Agonist	[4]
P2Y purinoceptor 6 (P2RY6)	TTNVSKA	P2RY6_HUMAN	Agonist	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-nucleotidase (NT5E)	OT7J5LT6	5NTD_HUMAN	Gene/Protein Processing	[6]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[7]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Gene/Protein Processing	[8]
Fibrinogen alpha chain (FGA)	OTMIHY80	FIBA_HUMAN	Protein Interaction/Cellular Processes	[7]
Fibrinogen beta chain (FGB)	OT6RKLI9	FIBB_HUMAN	Protein Interaction/Cellular Processes	[7]
Fibrinogen gamma chain (FGG)	OT5BJSEX	FIBG_HUMAN	Protein Interaction/Cellular Processes	[7]
Growth arrest-specific protein 6 (GAS6)	OTPOPUUE	GAS6_HUMAN	Drug Response	[9]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[10]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Post-Translational Modifications	[10]
Platelet basic protein (PPBP)	OT1FHGQS	CXCL7_HUMAN	Protein Interaction/Cellular Processes	[11]

------------------------------------------------------------------------------------

References

1	Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5.
2	Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57.
3	P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
4	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
5	Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
6	Stimulation of an alpha1-adrenergic receptor downregulates ecto-5' nucleotidase activity on the apical membrane of RPE cells. Purinergic Signal. 2006 Sep;2(3):499-507.
7	Moderation of the platelet releasate response by aspirin. Blood. 2007 Jun 1;109(11):4786-92. doi: 10.1182/blood-2006-07-038539. Epub 2007 Feb 15.
8	Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001 Mar;12(2):74-82. doi: 10.1080/09537100020031207.
9	Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J Thromb Haemost. 2005 Apr;3(4):733-41. doi: 10.1111/j.1538-7836.2005.01186.x. Epub 2005 Feb 23.
10	Cellular injury induces activation of MAPK via P2Y receptors. J Cell Biochem. 2004 Apr 1;91(5):938-50. doi: 10.1002/jcb.10774.
11	The role of nanoparticle size in hemocompatibility. Toxicology. 2009 Apr 28;258(2-3):139-47. doi: 10.1016/j.tox.2009.01.015. Epub 2009 Jan 22.
12	Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol. 2005 Jul 15;70(2):266-74.
13	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
14	Clinical pipeline report, company report or official report of AstraZeneca (2009).
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
16	Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56.
17	Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.
18	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
19	Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
20	Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005 Sep;94(3):593-8.
21	An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997 May;121(2):338-44.
22	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 323).
23	Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol. 2004 Nov 15;68(10):1995-2002.
24	2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem. 2003 Nov 6;46(23):4974-87.
25	2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. Biochem Pharmacol. 2004 Jul 15;68(2):231-7.
26	Two disparate ligand-binding sites in the human P2Y1 receptor. Nature. 2015 Apr 16;520(7547):317-21.
27	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
29	Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32.
30	Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
31	P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
32	Phosphatidylinositol 4,5-bisphosphate rescues TRPM4 channels from desensitization. J Biol Chem. 2005 Nov 25;280(47):39185-92.
33	Decavanadate modulates gating of TRPM4 cation channels. J Physiol. 2004 Nov 1;560(Pt 3):753-65.
34	A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 ch... Mol Pharmacol. 2006 Apr;69(4):1413-20.
35	9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br J Pharmacol. 2008 Apr;153(8):1697-705.
36	Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
37	Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim Biophys Acta. 2007 Sep;1770(9):1352-9.
38	Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
39	Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
40	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
41	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
42	Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
43	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
44	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
45	Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
46	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
47	High folic acid increases cell turnover and lowers differentiation and iron content in human HT29 colon cancer cells. Br J Nutr. 2008 Apr;99(4):703-8.
48	A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
49	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
50	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
51	Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
52	Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
53	Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
54	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
55	Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
56	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
57	Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA. Mol Cell Endocrinol. 2005 Jun 30;238(1-2):9-25. doi: 10.1016/j.mce.2005.04.005.
58	Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
59	Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int. 2008 Aug;28(7):997-1010. doi: 10.1111/j.1478-3231.2008.01744.x. Epub 2008 Apr 15.
60	Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
61	Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
62	Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
63	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
64	A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
65	The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
66	Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
67	Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
68	Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
69	[Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
70	Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
71	Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
72	[Unstable stenocardia: indicators of platelet activity and the effect of verapamil]. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1987;10(2):33-9.
73	Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
74	Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000 Apr;20(2):137-40. doi: 10.1097/00004714-200004000-00004.
75	Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
76	Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
77	Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med. 2004;36(7):552-7. doi: 10.1080/07853890410017386.
78	Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
79	Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000 Jun;83(6):688-95. doi: 10.1136/heart.83.6.688.
80	Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
81	Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
82	Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
83	Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
84	Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
85	Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
86	Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
87	Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
88	Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
89	SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
90	Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
91	A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
92	The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
93	Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
94	Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
95	Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep. 2016 Sep;36(3):1233-42. doi: 10.3892/or.2016.4944. Epub 2016 Jul 15.
96	Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002.
97	Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006 Jan;151(1):139. doi: 10.1016/j.ahj.2005.10.006.
98	Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114.
99	Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care. 2006 Feb;29(2):195-201. doi: 10.2337/diacare.29.02.06.dc05-1418.
100	Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
101	Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
102	Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. J Invasive Cardiol. 2006 Jan;18(1):6-12.
103	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
104	Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
105	Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
106	The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep. 2008 Jun;28(3):161-76. doi: 10.1042/BSR20080046.
107	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
108	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
109	The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
110	Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004 May;30(5):662-70. doi: 10.1165/rcmb.2003-0267OC. Epub 2003 Nov 20.
111	Molecular characterization of a toxicological tipping point during human stem cell differentiation. Reprod Toxicol. 2020 Jan;91:1-13. doi: 10.1016/j.reprotox.2019.10.001. Epub 2019 Oct 7.
112	Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
113	Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thromb Res. 2007;119(3):301-3. doi: 10.1016/j.thromres.2006.03.005. Epub 2006 May 3.
114	Specificity of increased des-gamma-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection. J Hepatol. 1987 Aug;5(1):27-9. doi: 10.1016/s0168-8278(87)80057-0.
115	Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost. 1995 Aug;74(2):693-7.
116	Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. doi: 10.1111/j.1538-7836.2006.02165.x. Epub 2006 Aug 14.
117	Androgen receptor-dependent transactivation of growth arrest-specific gene 6 mediates inhibitory effects of testosterone on vascular calcification. J Biol Chem. 2010 Mar 5;285(10):7537-44. doi: 10.1074/jbc.M109.055087. Epub 2010 Jan 4.
118	Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
119	Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Res. 2015 Sep 15;75(18):3699-705. doi: 10.1158/0008-5472.CAN-14-2887-T. Epub 2015 Jul 23.
120	Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):281-9.
121	Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004 Jan 15;16(2):204-11.
122	Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
123	Plasma levels of the growth arrest-specific gene 6 product (Gas6) and antiplatelet drug responsiveness in healthy subjects. J Thromb Haemost. 2006 Oct;4(10):2283-4. doi: 10.1111/j.1538-7836.2006.02155.x.